Home › Chemotherapy › Which Chemotherapy Drugs — Affect the Heart, Kidneys or Lungs?

Organ side effects

Which Chemotherapy Drugs Affect the Heart, Kidneys or Lungs?

Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed September 2026

Some chemotherapy drugs are known to affect specific organs — the heart, kidneys, or lungs. The drug involved, the total dose received over time, and your baseline organ health all shape the risk. Your team monitors each with specific tests designed to catch changes before they become serious.

Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed September 2026

Prescription-only medicine.

All chemotherapy medicines named on this page are prescription-only drugs, administered in a hospital or oncology day-care unit under specialist supervision. No chemotherapy can be started, changed, or stopped based on anything you read online — these decisions are made by a qualified oncologist who has reviewed your individual results. It is not suitable for everyone — see who this is not for below.

Talk to an oncologist

Leave your details and a member of the oncology team will call you back to answer questions about your treatment plan.

No charge for the call, and no obligation to book anything.

412Chemotherapy pages, written and reviewed

17Oncologists on the panel

10Centres across Hyderabad

41Locations across two states

In short

Certain chemotherapy drugs carry known risks to specific organs. Anthracyclines such as doxorubicin can affect the heart. Cisplatin can reduce kidney function. Bleomycin can cause lung scarring. Fluorouracil can cause coronary artery spasm. Each risk is managed through baseline testing, cycle-by-cycle monitoring, and cumulative dose limits guided by ASCO and NCCN recommendations.

In detail

Which chemotherapy drug affects which organ?

Anthracyclines — doxorubicin (Adriamycin, Doxovitol) and epirubicin (Farmorubicin) — are the drugs most commonly associated with heart effects. The risk accumulates with total dose received across all courses of treatment, not from any single infusion.

Fluorouracil (5-FU; Fivocil) and its oral form capecitabine (Xeloda, Capnat) can cause coronary artery spasm in a small proportion of patients. This may produce chest tightness or pain during or shortly after infusion.

Cisplatin (Cisteen, Platikem) is the drug most closely monitored for kidney effects. It can reduce the kidneys' ability to filter waste products, and the risk rises with each cycle. Ifosfamide also requires close kidney monitoring.

Bleomycin (Bleonco) can cause scarring of the lung tissue, and the risk rises with total lifetime dose. Gemcitabine, used in several regimens, can cause lung inflammation in a smaller proportion of patients.

Checklist

What monitoring tests does your team do — and when?

Before anthracyclines startEchocardiogram or MUGA scan to record your heart's baseline pumping function.
Before each cisplatin cycleBlood tests for creatinine and eGFR to check how well your kidneys are filtering.
Before bleomycinBreathing test (DLCO) and chest X-ray to record your lung baseline.
During 5-FU, if you report chest symptomsECG or cardiac monitoring during the infusion.
At milestones during anthracyclinesRepeat heart scan to compare against your baseline before continuing.

Eligibility

Who these chemotherapy drugs are not suitable for

Your oncologist decides eligibility for each drug individually, based on your organ function, your other medicines, and your overall health. Several groups are not given specific chemotherapy drugs because the risk of organ damage is too high.

People with significantly reduced heart function are not given anthracyclines such as doxorubicin or epirubicin without very close cardiac monitoring, and may not be candidates at all.
People with kidney impairment are not given cisplatin, or are given it only after specialist review of kidney function.
People with existing lung disease or previous high-dose bleomycin exposure are generally not given bleomycin again.
People who have already received the maximum cumulative dose of an anthracycline are not given more, regardless of current heart function.

Eligibility is decided by an oncologist who has reviewed your test results and treatment history — not by the drug's general profile alone.

Want to talk this through with an oncologist?

Leave your number and an oncology coordinator will call you back at a time that suits you.

At a glance

What do these medical terms mean?

CardiotoxicityDamage to the heart muscle, or a reduction in how well the heart pumps, caused by a medicine.

NephrotoxicityA medicine-caused reduction in the kidneys' ability to filter waste from the blood.

Pulmonary toxicityDamage or inflammation in the lung tissue caused by a medicine. Bleomycin is the chemotherapy most often linked to this.

Cumulative doseThe total amount of a drug received across all cycles. Some drugs have a lifetime maximum because their organ effects build rather than reset between cycles.

eGFRA calculation from blood tests showing how efficiently the kidneys are filtering. Used before each cisplatin cycle.

DLCOA breathing test measuring how well oxygen passes from the lungs into the bloodstream. Used to check lung health before and during bleomycin.

In detail

What happens when a test result changes or a limit is reached?

When a heart scan shows reduced function, anthracyclines are usually paused while the change is investigated. Whether treatment restarts depends on what is found and how much cumulative dose has already been given.

When kidney function falls below the level considered safe for cisplatin, the next cycle may be delayed, the dose adjusted after specialist review, or carboplatin (Kemocarb) used as a less nephrotoxic alternative.

For bleomycin, a change in lung function tests or new breathing symptoms typically means the drug is stopped. Lung scarring is not easily reversible, so the aim is to detect change before symptoms appear.

In detail

Which symptoms should you report to your team without waiting?

New or worsening breathlessness — whether during activity or at rest — should be reported the same day during any regimen that includes bleomycin or anthracyclines.

Chest pain or tightness during or after a 5-FU infusion needs immediate attention. Tell your nurse while it is happening, not at your next appointment.

A significant drop in urine output, or visible changes to your urine, during cisplatin treatment should be reported promptly. These can be earlier signals of kidney stress than blood tests alone show.

Still have a question about your treatment? Tell us what is on your chart and an oncologist will explain what it means for you, what to expect and what your schedule is likely to look like.

Talk to an oncologist 1800 202 8726

Common questions

Frequently asked questions

Can heart damage from doxorubicin be reversed?

Whether it can be reversed depends on how early it is caught. Minor changes in heart function detected on a routine echocardiogram are sometimes reversible with appropriate management. Established heart muscle damage from anthracyclines is less likely to fully recover. This is why the monitoring schedule matters — detecting change early keeps more options open. Ask your oncologist what your baseline scan showed and what change would trigger a pause in your treatment.

How is cisplatin different from carboplatin for kidney effects?

Cisplatin is significantly more damaging to kidney tissue than carboplatin. Carboplatin's dose is calculated from kidney function, and its toxicity profile is more likely to affect blood counts than kidneys. When kidney function is not sufficient for cisplatin, carboplatin is often used instead for cancers where either drug is active. Your oncologist will explain why one was chosen for your specific regimen.

Why is there a lifetime limit on doxorubicin?

Anthracycline damage to heart muscle cells accumulates with every dose and does not reset between cycles. Above a certain cumulative total, the risk of heart failure becomes unacceptable relative to any further benefit. Previous anthracycline treatment — for any cancer, at any point in your life — counts toward your lifetime total. Your oncologist will calculate how much has already been given before recommending a new regimen that includes an anthracycline.

Will bleomycin lung damage improve after treatment stops?

Bleomycin-related lung scarring, once established, does not fully reverse. This is why treatment is stopped when lung function tests show significant change, rather than waiting for breathlessness to develop. For most patients who are monitored carefully, the changes remain mild and do not cause lasting symptoms. How early the change is detected is what makes the difference — which is the purpose of DLCO testing before and during treatment.

Can I have chemotherapy if I already have kidney disease?

Yes, depending on the drug and how well your kidneys are currently working. Cisplatin is generally avoided when kidney function is significantly reduced, but many other chemotherapy drugs are safe at standard or adjusted doses. Your oncologist will review your kidney function before recommending a regimen and may adjust doses or choose an alternative. Kidney function is checked before each cycle of any drug with known kidney effects.

What is 5-FU doing to the heart — is it dangerous?

Fluorouracil can cause coronary artery spasm — the arteries supplying the heart go into temporary constriction, reducing blood flow. This usually causes chest tightness during or shortly after the infusion. If you feel chest symptoms, tell your nurse immediately; the infusion can be stopped. ASCO guidance recommends cardiac assessment before any further doses. Your team will decide whether continuing is safe or whether a different approach is more appropriate.

Who would be treating you

The medical oncologists on the CION panel

Chemotherapy is prescribed, dosed and supervised by a medical oncologist. These are the six on the CION panel.

Dr. Naresh Gundu

Medical Oncologist

MBBS · DNB Internal Medicine (Sir Gangaram, New Delhi) · DM Medical Oncology (AIIMS)

Call Book appointment

Dr. C. Raghavendra Reddy

Medical Oncologist

MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Kukatpally

Call Book appointment

Dr. Bharati Devi Gorantla

Medical Oncologist

MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK)

Call Book appointment

Dr. Owais Mohammed

Medical Oncologist

Call Book appointment

Dr. T. Raghavender Reddy

Medical Oncologist

MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · L.B. Nagar

Call Book appointment

Dr. N. Kiranmayee

Medical Oncologist

Call Book appointment

Which oncologist you see depends on the centre nearest you and on what your treatment involves. Tell us where you are and we will point you to the closest.

Talk it through

Reading about a medicine is not the same as being told what to expect

This page explains what the medicine does in general. What it cannot tell you is how your own regimen was chosen, what your schedule looks like, or which of these effects apply to you — that needs your reports and a conversation.

Free first consultation Second opinion on an existing plan 10 centres across Hyderabad

Speak to an oncologist

Share your details and the team will call you back to arrange a consultation or a second opinion.

Bring your reports if you have them. If you do not, come anyway.

list of links to other editorial pages, which base contract s2.1 permits explicitly. It contains no form, no phone number and no CTA button, so it does not turn this page into an advertisement. Generated by scripts/hub_update.py --include-out. -->

Full index